Abstract | Background: Aims: Methods: Treatment results, including side effects, for all microscopic colitis patients receiving anti-tumour necrosis factor therapy were registered at week 12 and at end of follow-up. Clinical remission was defined as a mean of <3 stools and <1 watery stools/day/week and clinical response as a 50% reduction of mean stool frequency/day/week. Induction and maintenance treatment was either adalimumab or infliximab. Results: The study cohort comprised 18 patients; mean age at diagnosis was 47 years (range 19-77). Ten and eight patients, respectively, received adalimumab and infliximab as first-line anti-tumour necrosis factor; seven patients received second-line anti-tumour necrosis factor due to non-response, loss of response or side effects. At week 12, 9/18 patients had achieved remission, 6/18 were responders and 3/18 were non-responders. Of the nine remission patients, 3/18 (16%) had long-lasting clinical remission post-induction therapy alone. Five patients (28%) (one first-line, four second-line anti-tumour necrosis factor) were in remission and one patient (6%) responded to maintenance treatment; follow-up was mean 22 (range 4-60) months. Six patients (33%) had minor, reversible side effects. Conclusions:
|
Authors | Niki Daferera, Henrik Hjortswang, Simone Ignatova, Andreas Münch |
Journal | United European gastroenterology journal
(United European Gastroenterol J)
Vol. 7
Issue 9
Pg. 1234-1240
(11 2019)
ISSN: 2050-6406 [Print] England |
PMID | 31700636
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © Author(s) 2019. |
Chemical References |
- Glucocorticoids
- Tumor Necrosis Factor Inhibitors
- Budesonide
- Infliximab
- Adalimumab
|
Topics |
- Adalimumab
(therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Budesonide
(therapeutic use)
- Colitis, Microscopic
(drug therapy)
- Female
- Glucocorticoids
(therapeutic use)
- Humans
- Infliximab
(therapeutic use)
- Male
- Middle Aged
- Retrospective Studies
- Treatment Failure
- Treatment Outcome
- Tumor Necrosis Factor Inhibitors
(therapeutic use)
- Young Adult
|